Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line treatment of adults with advanced non-small cell lung cancer (NSCLC) whose tumours have presumed EGFR mutations: information for SMC decision SMC2736

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes.

The aim of this work was to capture real-world evidence from Scotland on the use of first line systemic anti-cancer therapy (SACT) for treatment of advanced non-small cell lung cancer (NSCLC) with presumed epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution. This work is being done to assist SMC members when considering the submission for osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (SMC2736). This work will enable SMC members to assess the relevancy of information, provided as part of the assessment process, to patients in Scotland.

It was assumed that all patients who received a targeted treatment which inhibits the EGFR had either EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. It was not possible to access laboratory information or clinical notes to confirm this.

It was agreed with SMC members that this pilot report will only provide information on the numbers of patients treated and their baseline characteristics. No information will be provided on overall survival or subsequent treatments.